Name | PBRM1-BD2-IN-2 |
Description | PBRM1-BD2-IN-2, a selective and cell-active inhibitor of the polybromo-1 (PBRM1) bromodomain, exhibits binding affinity and inhibitory activity specifically targeting the PBRM1-BD2 domain, with Kd and IC50 values of 9.3 μM and 1.0 μM, respectively. This compound is utilized in cancer research. |
In vitro | PBRM1-BD2-IN-2 (0, 0.1, 1, and 10 μM; 5 days) selectively inhibits the growth of a PBRM1-dependent prostate cancer cell line. It exhibits binding affinity for PBRM1-BD2, PBRM1-BD5, SMARCA2B, and SMARCA4 with Kd values of 9.3 μM, 10.1 μM, 18.4 μM, and 69 μM, respectively, and inhibits PBRM1-BD2 with an IC50 of 1.0 μM[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 45 mg/mL (144.63 mM)
|
Keywords | PBRM1-BD2-IN-2 | PBRM1BD2IN2 |
Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | Anacardic Acid | Curcumin | dBET6 | Piflufolastat | Naphthol AS-E | Bisdemethoxycurcumin | GSK1379725A |
Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Inhibitor Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |